Clearmind announces U.S. patent publication for MDMA combination

Clearmind Medicine Inc., a clinical-stage biopharmaceutical company based in Vancouver, Canada, has published a U.S. patent application for a combination of MDMA and N-acylethanolamines aimed at treating post-traumatic stress disorder, anxiety, and eating disorders. The application, published by the United States Patent and Trademark Office, is a result of Clearmind's partnership with NeuroThera Labs Inc. (TSXV:NTLX). This collaboration has led to the creation of 13 patent applications worldwide.

The patent application outlines methods of combining MDMA with compounds such as palmitoylethanolamide (PEA) to potentially enhance the therapeutic potency of MDMA, reduce the required dosing, and mitigate side effects. This development comes after the U.S. Food and Drug Administration (FDA) published guidance on July 13, 2026, titled "Psychedelic Drugs: Considerations for Clinical Investigations."

The guidance discusses recommendations for sponsors developing psychedelic drugs for various medical conditions, including psychiatric and substance use disorders, and explicitly includes MDMA as a type of psychedelic drug.

The FDA guidance addresses several aspects of clinical development, such as trial design, conduct, data collection, subject safety, and requirements for new drug applications. The agency notes the challenges in developing psychedelic drugs due to their psychoactive effects and alterations in mood, cognition, and perception. Clearmind Medicine Inc. focuses on developing non-hallucinogenic, psychedelic-derived therapeutics for various disorders, with an intellectual property portfolio consisting of 19 patent families and 32 granted patents.